Anti-TNF alpha [D2E7 (Adalimumab)]

Absolute Antibody

Anti-TNF alpha [D2E7 (Adalimumab)]

7

Binds to soluble TNF-alpha, but not to lymphotoxin (TNF beta).

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab, unlike Infliximab (Ab00146), was shown to be cross-reactive with mouse TNF alpha (Arnoult 2017, PMID: 28584008).

ImmunoFluorescence, ELISA, ImmunoHistoChemistry, Neutralisation/Blocking

block; ELISA; IHC; IF

Research Use Only

Monoclonal

D2E7 (Adalimumab)

TNF

tumor necrosis factor

APC1 protein; DIF; TNF, macrophage-derived; TNF, monocyte-derived; TNFA; TNF-a; TNF-alpha; TNFSF2; TNLG1F; tumor necrosis factor; tumor necrosis factor ligand 1F; tumor necrosis factor ligand superfamily member 2; tumor necrosis factor-alpha

Rabbit

IgG

Tumor necrosis factor

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Human, Mouse

Human, Mouse

This antibody was generated by affinity maturation from the 2SD4 scFv, which in turn was selected on human TNF alpha by guided phage-display technology, using the murine anti-hTNF alpha antibody Mab32 as a template (c.f. also US Patent 6090382).

-20°C,2°C to 8°C

12352203